The role of microRNA deregulation in the pathogenesis of adrenocortical carcinoma

Adrenocortical carcinoma (ACC) is an aggressive tumor showing frequent metastatic spread and poor survival. Although recent genome-wide studies of ACC have contributed to our understanding of the disease, major challenges remain for both diagnostic and prognostic assessments. The aim of this study was to identify specific microRNAs (miRNAs) associated with malignancy and survival of ACC patients. miRNA expression profiles were determined in a series of ACC, adenoma, and normal cortices using microarray. A subset of miRNAs showed distinct expression patterns in the ACC compared with adrenal cortices and adenomas. Among others, miR-483-3p, miR-483-5p, miR-210, and miR-21 were found overexpressed, while miR-195, miR-497, and miR-1974 were underexpressed in ACC. Inhibition of miR-483-3p or miR-483-5p and overexpression of miR-195 or miR-497 reduced cell proliferation in human NCI-H295R ACC cells. In addition, downregulation of miR-483-3p, but not miR-483-5p, and increased expression of miR-195 or miR-497 led to significant induction of cell death. Protein expression of p53 upregulated modulator of apoptosis (PUMA), a potential target of miR-483-3p, was significantly decreased in ACC, and inversely correlated with miR-483-3p expression. In addition, high expression of miR-503, miR-1202, and miR-1275 were found significantly associated with shorter overall survival among patients with ACC (P values: 0.006, 0.005, and 0.042 respectively). In summary, we identified additional miRNAs associated with ACC, elucidated the functional role of four miRNAs in the pathogenesis of ACC cells, demonstrated the potential involvement of the pro-apoptotic factor PUMA (a miR-483-3p target) in adrenocortical tumors, and found novel miRNAs associated with survival in ACC.

[1]  T. Fojo,et al.  MicroRNA profiling of adrenocortical tumors reveals miR‐483 as a marker of malignancy , 2011, Cancer.

[2]  Jianfeng Jin,et al.  Coexpression of an intronic microRNA and its host gene reveals a potential role for miR-483-5p as an IGF2 partner , 2011, Molecular and Cellular Endocrinology.

[3]  C. Cheadle,et al.  Integrated genomic analysis of nodular tissue in macronodular adrenocortical hyperplasia: progression of tumorigenesis in a disorder associated with multiple benign lesions. , 2011, The Journal of clinical endocrinology and metabolism.

[4]  Lin Chen,et al.  microRNA-195 promotes apoptosis and suppresses tumorigenicity of human colorectal cancer cells. , 2010, Biochemical and biophysical research communications.

[5]  J. Sandgren,et al.  MicroRNA profiling of benign and malignant pheochromocytomas identifies novel diagnostic and therapeutic targets. , 2010, Endocrine-related cancer.

[6]  Johan Hansson,et al.  MicroRNA expression profiles associated with mutational status and survival in malignant melanoma. , 2010, The Journal of investigative dermatology.

[7]  M Suzuki,et al.  Explorer Induction of microRNAs , mir-155 , mir-222 , mir-424 and mir-503 , promotes monocytic differentiation through combinatorial regulation , 2010 .

[8]  Anindya Dutta,et al.  MiR-322/424 and -503 Are Induced during Muscle Differentiation and Promote Cell Cycle Quiescence and Differentiation by Down-Regulation of Cdc25A , 2010, Molecular biology of the cell.

[9]  E. Lalli,et al.  Regulation of insulin-like growth factor-mammalian target of rapamycin signaling by microRNA in childhood adrenocortical tumors. , 2010, Cancer research.

[10]  C. Croce,et al.  Oncogenic role of miR-483-3p at the IGF2/483 locus. , 2010, Cancer research.

[11]  Massimo Negrini,et al.  Micromarkers: miRNAs in cancer diagnosis and prognosis , 2010, Expert review of molecular diagnostics.

[12]  Y. E. Chen,et al.  miR-497 regulates neuronal death in mouse brain after transient focal cerebral ischemia , 2010, Neurobiology of Disease.

[13]  M. Bisceglia,et al.  Differential expression of microRNAs in human parathyroid carcinomas compared with normal parathyroid tissue. , 2010, Endocrine-related cancer.

[14]  D. Iliopoulos,et al.  MicroRNA signature in massive macronodular adrenocortical disease and implications for adrenocortical tumourigenesis , 2009, Clinical endocrinology.

[15]  H. Taubert,et al.  Elevated expression of microRNAs 155, 203, 210 and 222 in pancreatic tumors is associated with poorer survival , 2010, International journal of cancer.

[16]  Thomas Streichert,et al.  Identification of differentially expressed microRNAs in human male breast cancer , 2010, BMC Cancer.

[17]  Anthony J Gill,et al.  miR-195 and miR-483-5p Identified as Predictors of Poor Prognosis in Adrenocortical Cancer , 2009, Clinical Cancer Research.

[18]  C. Croce,et al.  MicroRNAs in cancer: small molecules with a huge impact. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Ricky T. Tong,et al.  Hypoxia-inducible mir-210 regulates normoxic gene expression involved in tumor initiation. , 2009, Molecular cell.

[20]  Xudong Dai,et al.  MicroRNA miR-210 modulates cellular response to hypoxia through the MYC antagonist MNT , 2009, Cell cycle.

[21]  P. Igaz,et al.  Integrative molecular bioinformatics study of human adrenocortical tumors: microRNA, tissue-specific target prediction, and pathway analysis. , 2009, Endocrine-related cancer.

[22]  C. Larsson,et al.  Transcriptional profiling enables molecular classification of adrenocortical tumours. , 2009, European journal of endocrinology.

[23]  J. Yun,et al.  MicroRNA‐195 suppresses tumorigenicity and regulates G1/S transition of human hepatocellular carcinoma cells , 2009, Hepatology.

[24]  A. Gill,et al.  Microarray gene expression and immunohistochemistry analyses of adrenocortical tumors identify IGF2 and Ki-67 as useful in differentiating carcinomas from adenomas. , 2009, Endocrine-related cancer.

[25]  D. Iliopoulos,et al.  MicroRNA signature of primary pigmented nodular adrenocortical disease: clinical correlations and regulation of Wnt signaling. , 2009, Cancer research.

[26]  Bertrand Dousset,et al.  Gene expression profiling reveals a new classification of adrenocortical tumors and identifies molecular predictors of malignancy and survival. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  Jinghuan Li,et al.  Potentially important microRNA cluster on chromosome 17p13.1 in primary peritoneal carcinoma , 2009, Modern Pathology.

[28]  Paul G. Gauger,et al.  Molecular Classification and Prognostication of Adrenocortical Tumors by Transcriptome Profiling , 2009, Clinical Cancer Research.

[29]  Qiong Shao,et al.  MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. , 2008, RNA.

[30]  C. Gomez-Sanchez,et al.  Microribonucleic acid-21 increases aldosterone secretion and proliferation in H295R human adrenocortical cells. , 2008, Endocrinology.

[31]  H. Allgayer,et al.  MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer , 2008, Oncogene.

[32]  Shuomin Zhu,et al.  MicroRNA-21 targets tumor suppressor genes in invasion and metastasis , 2008, Cell Research.

[33]  Carme Camps,et al.  hsa-miR-210 Is Induced by Hypoxia and Is an Independent Prognostic Factor in Breast Cancer , 2008, Clinical Cancer Research.

[34]  J. Bertherat,et al.  Loss of Heterozygosity of 17p13, With Possible Involvement of ACADVL and ALOX15B, in the Pathogenesis of Adrenocortical Tumors , 2008, Annals of surgery.

[35]  J. Cheng,et al.  Identification of miRNAs associated with tumorigenesis of retinoblastoma by miRNA microarray analysis , 2008, Child's Nervous System.

[36]  A. Fire,et al.  Patterns of known and novel small RNAs in human cervical cancer. , 2007, Cancer research.

[37]  Chris Sander,et al.  Quantitative technologies establish a novel microRNA profile of chronic lymphocytic leukemia. , 2007, Blood.

[38]  Shuomin Zhu,et al.  miR-21-mediated tumor growth , 2007, Oncogene.

[39]  R. Roth,et al.  Hypoxia, drug therapy and toxicity. , 2007, Pharmacology & therapeutics.

[40]  J. Bertherat,et al.  Mechanisms of Disease: adrenocortical tumors—molecular advances and clinical perspectives , 2006, Nature Clinical Practice Endocrinology &Metabolism.

[41]  J. Pouysségur,et al.  Hypoxia signalling in cancer and approaches to enforce tumour regression , 2006, Nature.

[42]  Joakim Lundeberg,et al.  Expression profiling of adrenocortical neoplasms suggests a molecular signature of malignancy. , 2005, Surgery.

[43]  C. Croce,et al.  MicroRNA gene expression deregulation in human breast cancer. , 2005, Cancer research.

[44]  K. Kosik,et al.  MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. , 2005, Cancer research.

[45]  F. Berger,et al.  Gene expression profiling of human adrenocortical tumors using complementary deoxyribonucleic Acid microarrays identifies several candidate genes as markers of malignancy. , 2005, The Journal of clinical endocrinology and metabolism.

[46]  S Miyano,et al.  Open source clustering software. , 2004, Bioinformatics.

[47]  R. DeLellis.  Pathology and genetics of tumours of endocrine organs , 2004 .

[48]  Paul G Gauger,et al.  Distinct transcriptional profiles of adrenocortical tumors uncovered by DNA microarray analysis. , 2003, The American journal of pathology.

[49]  E. Berg,et al.  World Health Organization Classification of Tumours , 2002 .

[50]  C. Larsson,et al.  Genetic aberrations in adrenocortical tumors detected using comparative genomic hybridization correlate with tumor size and malignancy. , 1996, Cancer research.